Nanobots Therapeutics

Therapeutics In-Motion

Nanobots Therapeutics is a deeptech company focused on developing and commercializing MotionTx platform.

MotionTx technology enables the development of unique therapeutic entities that penetrate tissues with superior efficacy, enhancing drug accumulation in target cells.  

The company is a spin-off of ICREA and IBEC and is the result of the research led by Prof. Samuel Sánchez.

Our science is pioneering the development of MotionTx platform, a new modality of therapeutic entities with unique properties to penetrate tissues and accumulate in target cells. What is MotionTx?   

New Modality

Novel class of drugs with unique tissue penetration capabilities

Platform Technology

Can carry a variety of drugs for different therapeutic indications

Targeted Delivery

Maximizing local routes of administration

Urease-powered nanobots for radionuclide bladder cancer therapy
Simó C, Serra-Casablancas M, Hortelao AC, Di Carlo V, Guallar-Garrido S, Plaza-García S, Rabanal RM, Ramos-Cabrer P, Yagüe B, Aguado L, Bardia L, Tosi S, Gómez-Vallejo V, Martín A, Patiño T, Julián E, Colombelli J, Llop J, Sánchez S.
Nat Nanotechnol. 2024 Jan 15 (online)

Swarming behavior and in vivo monitoring of enzymatic nanomotors within the bladder
Ana C. Hortelao, Cristina Simó, Maria Guix, Sandra Guallar-Garrido, Esther Julián, Diana Vilela, Luka Rejc, Pedro Ramos-Cabrer, Unai Cossío, Vanessa Gómez-Vallejo, Tania Patiño*, Jordi Llop*, Samuel Sánchez*.
Sci Robot, 2021 Mar 17;6(52)

Enzyme-Powered Gated Mesoporous Silica Nanomotors for On-Command Intracellular Payload Delivery
Antoni Llopis-Lorente, Alba García-Fernández, Nerea Murillo-Cremaes, Ana C. Hortelão, Tania Patiño, Reynaldo Villalonga, Félix Sancenón, Ramón Martínez-Máñez,* and Samuel Sánchez*.
ACS Nano 2019, 13, 12171−12183

Targeting 3D Bladder Cancer Spheroids with Urease-Powered Nanomotors
Ana C. Hortelão, Rafael Carrascosa, Nerea Murillo-Cremaes, Tania Patiño,* and Samuel Sánchez*.
ACS Nano 2019, 13, 429−439

MotionTx Platform will benefit patients by improving the accumulation of therapeutic drugs in target cells.


Bladder Cancer

Learn More  


Undisclosed indication

Samuel Sánchez

Academic Founder - Interim CEO & CSO

Marta Soler Grima


Andrés G Fernández

Co-Founder - Drug development advisor

Daniel Oliver

Co-Founder - Strategic advisor

Isaac Cabezas

Co-Founder - Finance advisor


Company creation

Read More

PreSeed round closing

Read More

Promising results in bladder cancer

Read More

Nanobots Tx at 4Y4N: watch it!

Read More

Get to know Nanobots Tx at South Summit 2024

Where? Madrid, La Nave, booth #122 When? June 5th If you want to know more about our technology and recent advances, just come and visit us!

Read More